Get the Stockscreener App
1,176.52
0.69%
7.345
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,176.52, with a volume of 1.81M.
It is up +0.69% in the last 24 hours and up +5.87% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,169.17
Open:
$1159.445
24h Volume:
1.81M
Relative Volume:
0.57
Market Cap:
$1.05T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
42.35
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-0.95%
1M Performance:
+5.87%
6M Performance:
+13.37%
1Y Performance:
+54.60%
1-Day Range:
$1,151.01
$1,187.95
1-Week Range:
$1,134.40
$1,196.29
52-Week Range:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,176.60 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.30 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
256.50 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.40 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.82 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
UBS reiterates Eli Lilly stock rating on ATAI acquisition - Investing.com
Biotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developers - QuotedData
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200 - markets.businessinsider.com
Eli Lilly files initial plans for $6.5B Generation Park manufacturing site - The Business Journals
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020The Stock Now Trades Above $1,200 - The Manila Times
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200 - GlobeNewswire Inc.
Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup - ChartMill
Eli Lilly stock trades near record territory as Mounjaro and Zepbound drive double digit growth - ad-hoc-news.de
Eli Lilly (LLY) Is Buying AtaiBeckley To Enter Psychedelic Mental Health Treatments - simplywall.st
Eli Lilly Bets Big on Psychedelics with $3.8 Billion Takeover of AtaiBeckley - EBC Financial Group
Eli Lilly's $3.8bn psychedelics bet is built on British science - Yahoo! Finance Canada
Jefferies downgrades Atai stock rating to hold on Lilly buyout - Investing.com
Biotech Growth Trust Portfolio Company AtaiBeckley To Be Acquired By Eli Lilly - DirectorsTalk Interviews
Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray - The Daily Upside
Mental Health Stocks Gaining Fresh Attention After Eli Lilly’s Psychedelic Deal - simplywall.st
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly - Yahoo Finance UK
U.S. pharmaceutical company Eli Lilly announced on the 16th that it has decided to acquire mental he.. - 매일경제
Roundup: Trump’s social posts / Lilly’s psychedelic bet / Visa’s stablecoin push - Baton Rouge Business Report
Eli Lilly Picks Ropes & Gray for $3.8 Billion Psychedelics Deal - Bloomberg Law News
Ropes & Gray, Latham Steer $3.8B Eli Lilly Mental Health Deal - Law360
Rapid Reactions: Eli Lilly Acquisition Highlights Momentum in Psychedelics for Mental Health - HMP Global Learning Network
Eli Lilly Acquires Psychedelics Specialist AtaiBeckleyWhat Investors Should Know (LLY) - Seeking Alpha
Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition - MedCity News
Lilly to buy psychedelic firm AtaiBeckley for up to $3.8 billion - Moneycontrol.com
Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock - Barchart.com
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover - Pharmaceutical Technology
Lilly acquiring firm developing psychedelic depression treatments for up to $3.8M - Inside INdiana Business
Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn - The Times
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics - BioPharma Dive
United Airlines Falls on Earnings; Eli Lilly Moves on Acquisition | Stock Movers - marketscreener.com
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker - Advisor Perspectives
ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit - BioWorld News
Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $3.8 billion - Yahoo Finance Singapore
Lilly enters psychedelic drug race with up to US$3.8 billion AtaiBeckley deal - BNN Bloomberg
Eli Lilly deal to buy AtaiBeckley boosts psychedelic stocks - Seeking Alpha
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships - Benzinga
Eli Lilly (LLY) Among Top Mega-Cap Healthcare Stocks with A+ Pro - GuruFocus
Lilly confirms arrival of new psychedelic age with $3.8 billion AtaiBeckley buy - The Pharma Letter
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
Eli Lilly to Acquire AtaiBeckley for $2.8 Billion - Pharmaceutical Executive
Eli Lilly and Company entered into an Agreement and Plan of Merger to acquire AtaiBeckley Inc. from Apeiron Investment Group Limited and others. - marketscreener.com
Eli Lilly (NYSE:LLY) Gains Momentum After FDA Drug Approval - Kalkine Media
Eli Lilly rises after AtaiBeckley purchase deal, RBC supportive - marketscreener.com
Lilly To Acquire AtaiBeckley In $2.8 Billion Deal - Pulse 2.0
Eli Lilly to acquire AtaiBeckley in deal worth up to $3.8 billion - MLex
Eli Lilly to buy AtaiBeckley in $2.8bn deal - Sharecast.com
Lilly to Acquire AtaiBeckley - Contract Pharma
AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion - Yahoo! Finance Canada
Eli Lilly confirms rumors: Makes a bid for AtaiBeckley - medwatch.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):